Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19050582 | 0.92 | POLB (0.33) | POLBALDH1A1PKML3MBTL1GAA | |
| SCHEMBL20089204 | 0.90 | POLB (0.32) | POLBALDH1A1GAA | |
| SCHEMBL22955339 | 0.87 | NCF1 (0.41) | POLBALDH1A1PKML3MBTL1GAA | |
| SCHEMBL18634444 | 0.84 | — | — | |
| SCHEMBL18745413 | 0.83 | NCF1 (0.30) | — | |
| SCHEMBL21743370 | 0.81 | HRH3 (0.37) | POLBALDH1A1PKML3MBTL1GAA | |
| SCHEMBL20375137 | 0.81 | POLB (0.33) | POLBALDH1A1PKML3MBTL1GAA | |
| SCHEMBL18737371 | 0.80 | POLB (0.30) | POLB | |
| SCHEMBL22477850 | 0.80 | NCF1 (0.41) | HRH3 | |
| SCHEMBL21466366 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230100559-A1 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-03-30 | — | — | US | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20210171490-A1 | RED-SHIFTED FLUOROPHORES | HOWARD HUGHES MEDICAL INSTITUTE | 2021-06-10 | — | — | US | disclosed |
| US-10934305-B2 | SHMT inhibitors | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200239488-A1 | SHMT Inhibitors | THE TRUSTEES OF PRINCETON UNIVERSITY | 2020-07-30 | — | — | US | disclosed |
| US-10646475-B2 | SHMT inhibitors | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180117010-A1 | SHMT Inhibitors | THE TRUSTEES OF PRINCETON UNIVERSITY | 2018-05-03 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180072751-A1 | SHMT Inhibitors | THE TRUSTEES OF PRINCETON UNIVERSITY | 2018-03-15 | — | — | US | disclosed |
| US-20180071232-A1 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INJURY OR DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-03-15 | — | — | US | disclosed |
| US-20170253586-A1 | Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II | MEDIFRON DBT INC. (KR) | 2017-09-07 | — | — | US | disclosed |
| US-9624211-B2 | Anti-cancer compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071232-A1 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INJURY OR DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C9, C1S | POLB 1125/4885ALDH1A1 1124/4885PKM 1625/4885 |
| US-20180072751-A1 | SHMT Inhibitors | SHMT1, SHMT2, BHMT | POLB 984/4885ALDH1A1 110/4885PKM 1744/4885 |
| US-10934305-B2 | SHMT inhibitors | SHMT1, SHMT2, BHMT | POLB 984/4885ALDH1A1 110/4885PKM 1744/4885 |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | POLB 4085/4885ALDH1A1 4030/4885PKM 2119/4885 |
| US-20230100559-A1 | Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism | SHMT2, PC, ME2 | POLB 1223/4885ALDH1A1 575/4885PKM 208/4885 |
| US-20200239488-A1 | SHMT Inhibitors | SHMT1, SHMT2, BHMT | POLB 981/4885ALDH1A1 117/4885PKM 540/4885 |
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | POLB 1045/4885ALDH1A1 2372/4885PKM 3407/4885 |
| US-20210171490-A1 | RED-SHIFTED FLUOROPHORES | TFEB, DDX21, CDC73 | POLB 3161/4885ALDH1A1 1847/4885PKM 2882/4885 |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | POLB 2949/4885ALDH1A1 1037/4885PKM 1327/4885 |
| US-20170253586-A1 | Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II | TRPV1, TRPV2, GPR17 | POLB 4158/4885ALDH1A1 1621/4885PKM 1083/4885 |
| US-20180117010-A1 | SHMT Inhibitors | SHMT1, SHMT2, BHMT | POLB 1475/4885ALDH1A1 216/4885PKM 1215/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | POLB 1045/4885ALDH1A1 2372/4885PKM 3407/4885 |
| US-10646475-B2 | SHMT inhibitors | SHMT1, SHMT2, BHMT | POLB 1475/4885ALDH1A1 216/4885PKM 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.